Sales, general and administrative expenditures ("SG&A") for the quarter ended December 31, 2007 totaled $495,000 as compared to $1,851,000 during the quarter ended December 31, 2006. This represents a reduction of $1,356,000, or 73%. For the year ended December 31, 2007, SG&A totaled $2,773,000 as compared to $5,691,000 for the year ended December 31, 2006. This represents a reduction of $2,918,000, or 51%.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.
With the exception of historical information, the statements set forth
above include forward-looking statements. Any
|SOURCE Cardiogenesis Corporation|
Copyright©2008 PR Newswire.
All rights reserved